In order to evaluate FVIII output and stability in adult mice, without confounding factors due to anti-FVIII immune responses, that are more likely to develop upon treatment at this age, we generated immune-deficient hemophilia A mice, by crossing F8 KO with Rag1 KO mice (RagHemoA). The gene discussed is F8; the disease is hemophilia A.